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Abstract 
Current antipsychotic medication is largely ineffective against the negative and cognitive 
symptoms of schizophrenia. One promising therapeutic development is to design new 
molecules that balance actions on dopamine D2 and D3 receptors to maximise benefits and 
limit adverse effects. This study used two rodent paradigms to investigate the action of the 
dopamine D3-preferring D3/D2 receptor partial agonist cariprazine. In adult male rats, 
cariprazine (0.03-0.3mg/kg i.p.), and the atypical antipsychotic aripiprazole (1-3mg/kg i.p.) 
caused dose-dependent reversal of a delay-induced impairment in novel object recognition 
(NOR). Treating neonatal rat pups with phencyclidine (PCP) and subsequent social isolation 
produced a syndrome of behavioral alterations in adulthood including hyperactivity in a novel 
arena, deficits in NOR and fear motivated learning and memory, and a reduction and change 
in pattern of social interaction accompanied by increased ultrasonic vocalisations (USVs). 
Acute administration of cariprazine (0.1 and 0.3mg/kg) and aripiprazole (3mg/kg) to resultant 
adult rats reduced neonatal PCP-social isolation induced locomotor hyperactivity and 
reversed NOR deficits. Cariprazine (0.3mg/kg) caused a limited reversal of the social 
interaction deficit but neither drug affected the change in USVs or the deficit in fear 
motivated learning and memory. Results suggest that in the behavioral tests investigated 
cariprazine is at least as effective as aripiprazole and in some paradigms it showed 
additional beneficial features further supporting the advantage of combined dopamine D3/D2 
receptor targeting. These findings support recent clinical studies demonstrating the efficacy 
of cariprazine in treatment of negative symptoms and functional impairment in schizophrenia 
patients. 
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1. Introduction 
Schizophrenia is a debilitating, lifelong psychiatric disorder affecting approximately 1% of the 
population. Current antipsychotics provide therapeutic benefit to the positive symptoms, but 
have relatively little impact on the negative (social withdrawal and anhedonia) and cognitive 
deficits (Keefe et al., 2007) which precede psychosis and show a stronger correlation to 
patient functional outcome (Green et al., 2004; Mintz and Kopelowicz, 2007). All current 
antipsychotics are dopamine D2 receptor antagonists, a property thought to contribute to the 
reduction in positive symptoms but also their high propensity for unwanted extrapyramidal 
side-effects and tardive dyskinesia limiting therapeutic benefit. Second generation atypical 
antipsychotics were developed in an attempt to improve therapy but still have limited effect on 
cognitive deficits or negative symptoms and many cause weight gain and metabolic 
abnormalities (Miyamoto et al., 2012). Thus new therapeutic agents operating through different 
pharmacological mechanisms are essential for more effective management of schizophrenia. 
One potential mechanism, preferential targeting of the dopamine D3 receptor over the 
dopamine D2 receptor, might provide effective relief of positive and negative symptoms 
combined with improved cognitive function (Gyertyán et al., 2008; Laszy et al., 2005; Millan 
and Brocco, 2008; Millan et al., 2008). 
Current antipsychotics lack selective discrimination of dopamine D2 and D3 receptors, however 
recent positron emission tomography studies (Howes et al., 2015) show these have a 
differential brain distribution. The D3 receptor is abundant in the ventral striatal mesolimbic 
system and frontal cortex but (unlike the D2 receptor) low in the dorsal striatum, which may 
account for the paucity of effect of D3 antagonists on locomotor activity in rodents and provides 
potential for few extrapyramidal symptom in clinical use in man (see reviews; (Heidbreder and 
Newman, 2010; Millan and Brocco, 2008). Both gene polymorphisms and increased post-
mortem brain D3 receptor protein levels have also been associated with patients who had 
schizophrenia. Furthermore converging evidence showing the receptors have contrasting roles 
on cognition in rodents, encouraged development of drugs with differential D2/D3 receptor 
pharmacology (Millan and Brocco, 2008; Sokoloff et al., 2006; Watson et al., 2012a). 
Cariprazine (RGH-188; N′-[trans-4-[2-[4-(2,3-dichlorophenyl)-1-piperazinyl]ethyl]cyclohexyl]-
N,Ndimethylurea, VraylarTM) is one such orally active, putative antipsychotic which is described 
as a dopamine D3 receptor preferring D3/D2 receptor partial agonist (Ágai-Csongor et al., 2012; 
Caccia et al., 2013). In vitro ligand binding and functional studies show that cariprazine has 6-
10 fold higher affinity for the human dopamine D3 than D2 receptor (Ki=0.085 and Ki=0.49 nM, 
respectively) and is a moderate affinity partial agonist at 5-HT1A receptors (Kiss et al., 2010). 
Positron emission tomography studies in the monkey confirmed that at the highest dose used 
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(300g/kg) cariprazine has >90% D2/D3 receptor occupancy in the striatum with only 30% 5-
HT1A receptor occupancy in the raphé consistent with the in vitro data (Seneca et al., 2011). 
Unlike other atypical antipsychotics, cariprazine shows a high and balanced occupancy of both 
D2 and D3 receptors in rodents as seen in schizophrenia patients (Kiss et al., 2012; Slifstein et 
al., 2013). This unique pharmacological profile suggests cariprazine may have antipsychotic 
effects combined with beneficial effects on cognitive and negative symptoms above that seen 
with current antipsychotics. Indeed, cariprazine is active in several rodent models predictive of 
‘antipsychotic-like’ activity; including the conditioned avoidance response and inhibition of 
amphetamine-induced hypermotility, without evidence of induction of ‘cataleptic-like’ activity 
(Gyertyán et al., 2011). Furthermore cariprazine has been shown to attenuate the chronic mild 
stress-induced decrease in sucrose intake in rats which has been suggested by some groups 
to be a model of anhedonia; a common symptom of schizophrenia as well as depression 
(Papp et al., 2014). Positive results have been obtained from phase II and III clinical trials in 
schizophrenia and bipolar mania (Calabrese et al., 2015; Durgam et al., 2014, 2015; Grunder, 
2010; Sachs et al., 2015). Recently cariprazine was also shown to produce significant 
improvement against placebo on Positive and Negative Syndrome Scale total in a 6 week 
phase III clinical trial (Kane et al., 2015) in patients with an acute exacerbation of 
schizophrenia and has now received approval by the FDA for the treatment of schizophrenia 
and acute treatment of manic or mixed episodes associated with bipolar I disorder 
(McCormack, 2015). 
However the preclinical activity of cariprazine against cognitive deficits has so far been 
limited to reversal of pharmacological impairments in learning and memory. These include 
scopolamine-induced deficits in a rat water-labyrinth task (where a bell shaped dose-response 
pattern was observed; Gyertyán et al., 2011) and PCP-induced deficits in rat and mouse tests 
of visual recognition memory, attentional set shifting/reversal learning and social 
interaction/social recognition memory (Adham et al., 2012; Zimnisky et al., 2013).  
Rearing rats in social isolation from weaning produces long-term neurodevelopmental, 
behavioral, structural and neurochemical alterations with translational relevance to a spectrum 
of changes seen schizophrenia (Fone and Porkess, 2008; Jones et al., 2011b; Lapiz et al., 
2003) including visual learning, social cognition, reversal learning and attentional set shifting 
deficits (Bianchi et al., 2006; Fone et al., 1996; Fone and Porkess, 2008; King et al., 2009; 
Marsden et al., 2011; Meffre et al., 2012). Importantly in studies examining new potential 
therapies for schizophrenia compounds with divergent pharmacology including dopamine D3 
or 5-HT6 receptor antagonists and mGluR2/3 or nicotinic receptor agonists (Jones et al., 2011a; 
King et al., 2013; Marsden et al., 2011; Watson et al., 2012b) reverse components of the 
isolation-induced syndrome, suggesting this model has useful pharmacological sensitivity. 
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Neonatal treatment of rats with the non-competitive NMDA receptor antagonist, phencyclidine 
(PCP), disrupts neuronal development and synaptogenesis and also reproduces in adulthood 
many of the behavioural features akin to schizophrenia, including hyperactivity to 
amphetamine, attenuated sensorimotor gating and deficits in cognition (Bubenikova-Valesova 
et al., 2008; Ingallinesi et al., 2015; Mouri et al., 2007). We recently showed that combining 
neonatal PCP administration with subsequent isolation rearing, as a novel ‘dual-hit’ 
neurodevelopmental model (Lim et al., 2012), causes all the behavioral changes seen with 
isolation alone (Gaskin et al., 2014), but importantly also attenuated social interaction 
(McIntosh et al., 2012) which may be a useful predictive index of negative symptoms such as 
social withdrawal (Sams-Dodd, 1999; Wilson and Koenig, 2014). The current study therefore 
recorded a battery of behavioral tests in neonatal PCP treated and isolation-reared rats and 
controls to examine reversal of surrogate markers for positive, negative and cognitive deficits 
by the novel potential antipsychotic compound, cariprazine. 
Initially this study compared the effects of cariprazine and aripiprazole on cognition in 
a novel object recognition (NOR) test of memory using a model of natural forgetting in 
adolescent rats to establish suitable doses to be used in the main neurodevelopmental 
rodent model. This paradigm was selected because of pharmacological sensitivity to drugs 
which modify dopaminergic activity, reliability, and wide recognition of its translational 
relevance to visual learning and memory deficits seen in schizophrenia (Lyon et al., 2012; 
Rajagopal et al., 2014), which are resistant to current medication.  Secondly, in the main 
study, cariprazine and aripiprazole were compared in rats treated with neonatal PCP 
followed by social isolation to determine their ability to reverse behavioral changes in tests 
chosen to have relevance to the positive, negative and cognitive deficits seen in patients with 
schizophrenia. 
 
2. Experimental procedures 
2.1. Animals 
Male Lister hooded rats were used in all experiments. In the time-delayed NOR studies 
adolescent rats (Charles River UK weighing between 175-200g) were housed in groups of 
four and allowed to habituate for a week before testing. For the combined neonatal PCP and 
social isolation experiment (Gaskin et al., 2014) litters of five male Lister hooded pups 
arrived with their dam on post-natal day (PND) 3-4 (Charles River UK). Pups from each litter 
were injected with either sterile saline or PCP HCl (10mg/kg s.c.) on PND 7, 9 and 11. Pups 
were weaned on PND 24. Those pups receiving saline were housed in conventional cages 
(50 x 33 x 26cm) in groups of four while rats given PCP were housed in social isolation (41 x 
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24 x 20cm) such that isolates remained in auditory and olfactory contact with their litter 
mates but had no physical contact with conspecifics. Rats were isolated for five weeks 
before undergoing a battery of behavioral tasks, arranged in order of least to most aversive 
(to minimise any sequential effect on subsequent tasks) at approximately one week 
intervals. In all experiments food and water was available ad libitum and rats were housed 
under 12h light/dark cycle (lights on 07.00h), temperature 21 ± 2 °C, 55 ± 10 % humidity. All 
experiments were conducted in accordance with the Animals (Scientific Procedures) Act, 
1986 and ARRIVE guidelines with approval of University of Nottingham Local Ethical 
Committee and all efforts were made to minimise animal suffering, reduce the number of 
animals used, and utilise alternatives to in vivo techniques, if available. 
2.2 Experimental Design 
All behavioural studies were performed between 08.00 and 16.00h and following every test 
the apparatus was thoroughly cleaned with 20%v/v ethanol and dried to remove odor cues. 
All studies were performed using a blind protocol, so that the observer was unaware of drug 
treatment. The majority of studies were performed on rats which received both neonatal PCP 
and were subsequently reared in social isolation following weaning from the dam. The 
separate impact of exposure to each of these two manipulations has been thoroughly 
studied before (for reviews see (Bubenikova-Valesova et al., 2008; Fone and Porkess, 2008; 
Jones et al., 2011b)) and compared with the combined treatment by us (Gaskin et al., 2014). 
Isolation alone in Lister hooded rats does not attenuate social interaction (a useful index of 
negative symptoms) while neonatal PCP combined with isolation does, making this dual 
manipulation the method of choice for use herein. This study was designed to compare the 
ability of cariprazine and aripiprazole to reverse the resultant behavioral syndrome and not to 
determine which changes were produced by either neonatal PCP or isolation, so these 
separate groups were not included. To further reduce unnecessary use of animals, in 
accordance with the 3Rs principle and ARRIVE guidelines, the effect of cariprazine was 
compared to that of an antipsychotic in combined PCP/isolation-reared rats rather than to 
the effect of cariprazine in vehicle group-housed controls which substantially reduced the 
number of rats utilised. In order to ascertain any potential confounding non-specific 
‘sedatory-like’ motor effect of either drug, indices of locomotor activity were carefully 
monitored in each behavioral task and this is discussed later. 
2.3. Drugs and Dosing 
For time-delay NOR studies cariprazine (0.03-0.3mg/kg dissolved in 0.154M saline) or 
aripiprazole (0.3-3.0mg/kg suspended in distilled water with 2% Tween 80) were injected i.p. 
in a volume of 2ml/kg or 10ml/kg, respectively, 30min prior to the familiarisation trial. Based 
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on these data (and previous behavioral studies showing lack of sedative or cataleptic effects 
at these cariprazine doses (Gyertyán et al., 2011; Gyertyán et al., 2008; Papp et al., 2014)) 
cariprazine (0.1 and 0.3mg/kg) and aripiprazole (3mg/kg) were selected for the combined 
neonatal PCP and social isolation experiment. Treatments were administered 30min prior to 
each behavioral test, except for the conditioned freezing associative learning response task 
where they were given immediately after the third foot shock on the conditioning day and 
30min prior to testing on days two and three. Drug administration was given immediately 
after (and not before) conditioning to prevent any drug effect on perception of and/or 
response to the foot shock but enable interference with consolidation, and thus ensure 
detection of any specific effects on learning and memory. 
2.4. Spontaneous locomotor activity in a novel arena  
Isolation rearing of rats (both alone and combined with neonatal PCP) causes 
developmental induction of a reproducible hyperactivity in response to placement in a novel 
arena, regarded as a surrogate marker for striatal dopamine hyperactivity akin to positive 
symptoms of schizophrenia, which is attenuated by acute injection of several antipsychotics 
(Fabricius et al., 2010; Fone and Porkess, 2008; McIntosh et al., 2013). Locomotor activity in 
a novel arena was therefore measured initially in drug-free rats to confirm development of 
the isolation syndrome and, one week later, to compare reversal by cariprazine and 
aripiprazole. Five weeks after weaning, spontaneous locomotor and rearing activity was 
recorded for 1h in an unfamiliar Perspex arena (39cm x 23.5cm x 24.5cm) using a 
computerised infra-red activity system (Photobeam Activity System- Home Cage, San Diego 
Instruments, CA, USA). Horizontal ambulatory activity was measured as the consecutive 
interruption of two adjacent lower beams, while the number of rears was measured by 
interruption of a separate layer of upper beams. Cumulative beam-breaks were automatically 
recorded in 5min time bins for the test duration. Rats received no drug treatment. 
Six weeks after weaning, the effects of cariprazine and aripiprazole on spontaneous 
locomotor and rearing activity were recorded under the same conditions. Rats were 
assigned to each treatment group in a pseudorandom order using a balanced design to take 
into account litter, weight and locomotor performance in the previous trial. 
2.5. Novel object recognition task 
According to the MATRICS initiative NOR in rodents maps to the visual learning and 
memory cognitive domain which is attenuated in schizophrenia (Pelletier et al., 2005). NOR 
is widely regarded as a pertinent cognitive task to assess reversal of recognition memory by 
antipsychotic drugs because of reliability, knowledge of underlying circuits (Lyon et al., 2012; 
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Rajagopal et al., 2014) and its differential response to dopamine D2 (which impair) and D3 
(which restore) receptor antagonists (Watson et al., 2012b). Furthermore time-delay (natural) 
forgetting of NOR is robustly shorter in rats reared in isolation (both alone and combined with 
neonatal PCP (Gaskin et al., 2014)) than group-housed littermates and this deficit is 
reversed by antipsychotics (McIntosh et al., 2013) and drugs under development as 
adjunctive treatment for cognitive impairment (Jones et al., 2011a; Watson et al., 2012a). 
The NOR task was adapted from Ennaceur and Delacour (Ennaceur and Delacour, 1988) 
and is in routine use in our laboratory (Bianchi et al., 2006; King et al., 2004; Watson et al., 
2012a; Watson et al., 2012b). 
In all studies NOR was assessed 24h after 1h habituation to the apparatus, which also 
served to collect locomotor activity data in the PCP/social isolation rearing study (see 
spontaneous locomotor activity above). In studies in group-housed adolescent rats, to select 
doses of cariprazine and aripiprazole for the isolation study, the effect of drugs was 
examined on a delay-induced impairment of NOR using a 4h ITI chosen because normal, 
vehicle treated adolescent group-housed rats can’t discriminate the novel from familiar 
object with this ITI (Watson et al., 2012a). Performance of NOR is highly dependent on the 
objects used (Li et al., 2014); the close visual resemblance of objects in this task explains 
why such short ITIs impair performance and justifies selection of this particular trial interval. 
Furthermore previous validation studies established that rats do not show preferential 
exploration of the plain or striped objects, so any increase in exploration of the latter is not 
due to enhanced sensory motivation towards it.  A shorter ITI of 2min, where group-housed, 
vehicle-treated rats readily discriminate the novel object, was also used to examine any 
possible amnesic drug effects. These dose-response studies used a within-
subjects/repeated-measures design such that each rat received every dose of the chosen 
drug and its vehicle in a pseudorandom order; being tested on four separate occasions, at 
one week intervals. In studies with PCP isolation rats NOR was conducted in an identical 
manner but a 2h ITI was selected because these rats show more rapid natural, time delay-
induced forgetting and unlike group-housed littermate controls are unable to discriminate 
after this time. Thus a 2h ITI is ideal to examine drug-induced reversal of PCP/isolate-
induced impairment of NOR. 
In both studies on the test day rats were briefly reacclimatised to the arena for 3min before 
being returned to the home cage for 1min. During the familiarisation trial two identical objects 
(plastic bottles, 8cm high and 5cm diameter, wrapped in white masking tape) were placed in 
opposite corners of the arena (5cm from the side and 10cm from the end wall). The rat was 
returned to the arena for 3min and exploration of each identical objects recorded with 
stopwatches. After a 2h inter-trial interval (ITI) in the home cage the rat was returned to the 
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arena with one familiar and one novel object (identical size and shape bottle wrapped with 4 
black stripes 1.2cm in width). During this second, choice, trial exploration of each object was 
recorded for 3min. Exploratory behavior was defined as sniffing, licking, touching, and direct 
attention to the object with active vibrissae while the nose was within 1cm of the object. 
Climbing on or chewing the object was not considered as exploration and not recorded. 
Object exploration time during the choice trial was used to determine the discrimination ratio 
(time at novel - time at familiar/ total choice trial object exploration). 
2.6. Social interaction 
Assessment of the social behavioral repertoire between unfamiliar conspecifics is thought to 
be ethologically appropriate to monitor social withdrawal, a negative symptom associated 
with schizophrenia (Sams-Dodd, 1999; Wilson and Koenig, 2014). Social interaction was 
therefore assessed seven weeks after weaning. Rats were paired with weight-matched 
conspecifics from a different litter and housing cage of the same developmental condition 
and acute drug treatment. Rats were lightly coloured on the back with red or blue hair spray 
(UVGlow, Superdrug, randomly assigned) 30min prior to the test, to aid automated tracking 
(Ethovision XT ver8.5, Noldus). Each pair was placed in an open arena (75cm diameter, 
45cm walls), under dim light (40 lux) for 10min. Movement was automatically tracked while 
the behavior of each rat (anogenital sniffing, body sniffing, boxing and biting, crawling under 
and over, following, lying side-by-side and pinning) were scored from the video-recording by 
a scorer blind to treatment group. As the actual behavior of each rat in the pair is not 
independent of the action of the partner the mean duration of each individual behavior, total 
behavior and distance moved was calculated for each pair and the subsequent data 
analysed such that the N value represents the number of pairs. As an additional measure to 
record communication during social interaction ultrasonic vocalisation was recorded using an 
electret microphone (Emkay, Avisoft Bioacoustics, Germany) with optimal frequency 
responses at approximately 20–85kHz (to separately record 22kHz alarm and 50kHz pro-
social calls), connected to an ultrasound detection unit (Ultrasound Gate (USG) customised 
model 112, Avisoft Bioacoustics, Berlin). The resulting signal was digitalised and saved as 
.wav files. The temporal and frequency characteristic of every call was extracted using 
associated Avisoft analysis software (SAS-Lab Pro, v 4.38, Avisoft Bioacoustics, Berlin). 
Once calls had been automatically identified, they were verified by eye before accepting the 
measurement output for further statistical analysis. A Log10(x+1) transformation was used to 
normalise USV data prior to parametric statistical analysis. 
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2.7. Conditioned freezing response 
Associative learning including memory of preference conditioning is impaired in 
schizophrenia (Herbener, 2009) and resistant to antipsychotic medication (Kucharska-
Pietura et al., 2012). A fear motivated conditioned associated learning task was therefore 
used to measure amygdala- and/or hippocampal-dependent working-memory based on a 
protocol previously described by us (Jones et al., 2011a; McIntosh et al., 2013; Woods et al., 
2012). The conditioned freezing response (CFR) was examined eight weeks after weaning in 
a two chamber shuttle box with light and dark sides (27 x 25 x 25cm), separated by an 
automated door (8 x 8cm), with wire grid floors (PanLab, Slab, Barcelona, Spain) using a 
three day test protocol previously described (Jones et al., 2011a; McIntosh et al., 2013; 
Woods et al., 2012). On the first (conditioning) day rats were placed in the light side of the 
chamber. After 30s the door opened and the latency to cross into the dark side was recorded 
as an index of anxiety using a floor sensor which also closed the door (ShutAvoid, software 
v.1.8.2., Panlab S.L, USA). After 30s in the dark side a 5s conditioning stimulus (CS, light 
and 3kHz, 89dB tone) was immediately followed by delivery of the unconditioned stimulus 
(US, 1s 0.4mA footshock during the last second of the CS) through the grid floor. A further 
two consecutive CS/US were delivered separated by 55s. Time spent freezing (completely 
immobile except for respiration in a hunched posture with inactive vibrissae) between shocks 
was recorded by stopwatch. After 24 and 48h post-conditioning rats were returned to the 
dark side for 300s without CS/US and time spent freezing recorded as an index of 
associative learning and memory (Woods et al., 2012). During the extinction trial (48h post 
conditioning) the CS alone was presented after 300s and freezing recorded for a further 
300s. Behavior was also recorded through a camera in the roof of the CFR chamber using 
Ethovision (Nodulous) to enable re-assessment if required. 
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2.8. Tissue collection 
One week after the end of the behavioral studies rats were injected with vehicle or drug and 
30min later mixed arteriovenous trunk blood (in K2EDTA vials which were centrifuged at 4°C 
for 5min at 1200G) and brain tissue (frontal cortex and hippocampus) was collected and 
stored at -80°C for subsequent measurement of drug concentrations (in plasma and brain) 
by using liquid chromatography–mass spectrometry according to the methods described 
before (Gyertyán et al., 2011). 
2.9. Statistical analysis 
Locomotor activity time-course data were analysed using repeated measures analysis of 
variance (ANOVA) with treatment and housing as main factors and time as the repeated 
measure.  The cumulative locomotor activity data were analysed with two-way ANOVA with 
Bonferroni post-hoc test. Cumulative exploratory times during the familiarisation and choice 
trials of NOR were compared and the pattern of exploration during the choice trial was 
analysed using multivariant repeated measures ANOVA (with object as the repeated 
measure). To take account of any individual difference in object exploration between rats 
raw NOD data was converted to a discrimination ratio (D2 = (novel-familiar 
times)/(novel+familiar times)) analysed by two-way ANOVA with Bonferroni post-hoc. The 
individual behavioral components in the social interaction test, latency to enter the dark 
chamber in the CFR paradigm, and the Log10(x+1) transformed (normalised) USV data were 
analysed using two-way ANOVA with Bonferroni post-hoc while freezing behavior 24 and 
48h post-conditioning in the CFR was analysed with two-way repeated measures ANOVA 
with treatment and housing as variables and time as the repeated measure.  Given the 
unbalanced nature of the groups planned post-hoc comparisons were used. These were; 
vehicle/group-housed/vehicle (Veh/Soc/Veh) vs PCP/isolate/vehicle (PCP/Iso/Veh), 
PCP/Iso/Veh vs PCP/isolate/cariprazine 0.1mg/kg (PCP/Iso/Car0.1), PCP/Iso/Veh vs 
PCP/isolate/cariprazine 0.3mg/kg (PCP/Iso/Car0.3), and PCP/Iso/Veh vs 
PCP/isolate/aripiprazole 3mg/kg (PCP/Iso/Ari). Data was analysed using Prism 6 and SPSS 
software, with P<0.05 being considered significant. All data are presented as mean±SEM. 
 
3. Results 
3.1. Effect of cariprazine and aripiprazole on natural forgetting in the NOR task 
To assess any pro-cognitive effect in normal rats, the ability of both cariprazine and 
aripiprazole to reverse a time-delay-induced impairment in a two trial visual recognition 
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paradigm (NOR) was examined by selecting a 4h ITI (Fig. 1A and C) to produce natural 
forgetting. In both drug studies vehicle treated control group-housed adolescent rats were 
unable to discriminate the novel from the familiar object during the choice trial. Both 
cariprazine (Fig. 1A, object x drug: F(3,44) = 6.576, p<0.01) and aripiprazole (Fig. 1C, object x 
drug; F(3,44) = 3.315, p<0.05) improved object recognition, such that rats given the two 
highest doses of each drug spent significantly longer exploring the novel than the familiar 
object (cariprazine; 0.1mg/kg p<0.01, 0.3mg/kg p<0.001, aripiprazole; 1mg/kg p<0.05, 
3mg/kg p<0.001). This improvement in performance was confirmed by the concomitant 
significant main effect of each drug on the discrimination ratio (cariprazine; Fig. 1B, F(3,44) = 
7.670, p<0.001, and aripiprazole; Fig. 1D, F(1,44) = 3.570, p<0.05) although this only reached 
significance (p<0.001) from vehicle with the highest dose of cariprazine (0.3mg/kg) and not 
with aripiprazole. Although the effect of aripiprazole on the discrimination ratio failed to show 
any post-hoc significance even at the highest dose this was probably due to a slightly larger 
variation in the vehicle results for this study. 
During the familiarisation trials neither cariprazine nor aripiprazole produced any significant 
object place preference (Table 1, cariprazine; F(1,44) = 0.095, p=0.780, aripiprazole; F(1,44) = 
0.011, p=0.916). Total object exploration during the choice trial was lower than that in the 
familiarisation trial in all groups in both drug studies (Table 1, cariprazine; trial F(1,44) = 
67.081, p<0.001, aripiprazole; trial F(3,44) = 23.241, p<0.001) but there were no trial x drug 
treatment interactions (cariprazine; F(3,44) = 1.980, p=0.131, aripiprazole; F(3,44) = 0.845, 
p=0.477). In addition, drug treatment had no significant main effect on total exploration 
during the familiarisation (cariprazine; F(3,44) = 2.505, p=0.071, aripiprazole; F(3,44) = 1.123, 
p=0.350) or choice (cariprazine; F(3,44) = 0.941, p=0.429, aripiprazole; F(3,44) = 0.247, 
p=0.863) trials. Thus both drugs caused a specific redistribution of exploration towards the 
novel object during the choice trial without any non-specific change in exploration in either 
trial consistent with this being due to a specific effect on cognition and not a non-specific 
‘sedative-like’ effect on locomotion or attention. 
3.2. Effect of cariprazine and aripiprazole on NOR using a short intertrial interval 
To ensure that neither drug impaired NOR, in two further groups of rats the effect of 
cariprazine and aripiprazole was examined on the pattern of NOR using a short ITI of 2min 
where vehicle treated rats were readily able to discriminate the novel from the familiar object 
(Fig. 2A and C). Neither cariprazine (Fig. 2A) nor aripiprazole (Fig. 2C) had any significant 
effect on the pattern of object discrimination (object x drug; cariprazine; F(3,44) = 2.335, 
p=0.087, aripiprazole; F(3,44) = 0.220, p=0.882) during the choice trial. Thus irrespective of 
the dose of either drug, rats spent significantly more time exploring the novel than the 
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familiar object (all P<0.001) during the choice trial. Consistent with this observation from the 
raw data neither cariprazine (Fig. 2B, F(3,44) = 2.217, p=0.100) nor aripiprazole (Fig. 2D, F(1,44) 
= 0.214, p=0.886) had any significant effect on the discrimination ratio which was 
consistently higher than chance (d2=0).  
Neither drug treatment induced any preference for object location during the familiarisation 
trial (Table 1, cariprazine F(1,44) = 0.238, p=0.829, aripiprazole; F(1,44) = 0.604, p=0.441). As 
expected the total object exploration was reduced in the second choice compared to the 
familiarisation trial (cariprazine; F(3,44) = 0.845, p=0.477, aripiprazole; F(1,44) = 14.958, 
p<0.001) but neither cariprazine (trial x drug; F(3,44) = 0.939, p=0.430) nor aripiprazole (trial x 
drug; F(3,44) = 0.490, p=0.691) had any effect on the magnitude of this reduction nor did they 
have a main effect on total exploration during either the familiarisation (cariprazine; F(3,44) = 
2.127, p=0.110, aripiprazole; F(3,44) = 2.241, p=0.097) or choice trials (cariprazine; F(3,44) = 
1.948, p=0.138, aripiprazole; F(3,44) = 0.462, p=0.710). 
3.3. Effect of combined neonatal PCP and social isolation on locomotor activity and 
rearing behavior in a novel arena 
During a one hour, drug naïve, test session neonatal rats that had been treated with PCP 
and housed in social isolation from weaning for five weeks were hyperactive, showing higher 
horizontal ambulation (total beam breaks; vehicle/group-housed; 1737 ± 132, PCP/isolate; 
2012 ± 44; F(1,73) = 6.423, p<0.05) and more rears (total beam breaks; vehicle/group-housed; 
142 ± 16, PCP/isolate; 180 ± 6; F(1,73) = 0.604, p<0.01) compared to those given neonatal 
vehicle injections and housed in social groups. This confirmed the expected 
neurodevelopmental syndrome had been induced by the dual-hit early-life intervention and 
was used to ascertain there was no marked difference in activity between rats assigned by 
lots to vehicle, cariprazine or aripiprazole groups prior to drug testing. 
3.4. Effect of acute cariprazine or aripiprazole on locomotor activity in a novel 
arena in rats treated with neonatal PCP and housed in social isolation 
One week later the ability of cariprazine and aripiprazole to reverse the PCP/isolation 
induced hyper-reactivity to the novel environment was examined in the same boxes. Over 
the entire 1h period PCP/Iso/Veh rats exhibited higher locomotor counts than any other 
group (Fig. 3A). Although this was not significantly higher than Veh/Soc/Veh controls they 
displayed significantly more rears than the latter. Thus there was a main effect of acute drug 
treatment (F(3,75) = 21.763, p<0.001) on the total locomotor activity but no main effect of early 
life/housing (F(3,75) = 2.421, p=0.124). PCP-isolate rats treated with either cariprazine (both 
doses) or aripiprazole made significantly fewer horizontal beam breaks than the 
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PCP/Iso/Veh group (all p<0.001). Analysis of the time course (data not shown) revealed a 
significant time x acute treatment interaction F(11,770) = 2.004, p<0.01) but no significant time 
x housing interaction (F(33,770) = 1.359, p=0.188) suggesting that activity declined at the same 
rate irrespective of early-life housing but was attenuated by acute treatment with either drug. 
A similar profile was seen with the total number of rears which was increased by PCP/Iso 
(main effect F(3,73) = 19.582, p<0.001) and reduced by acute drug treatment (F(3,73) = 15.452, 
p<0.001). The PCP/Iso/Veh rats made significantly more rears than the Veh/Soc/Veh group 
(Fig. 3B, p<0.001) but this was attenuated in cariprazine (at both doses) and aripiprazole 
treatment (all p<0.001 compared to PCP/Iso/Veh). Repeated measures ANOVA of the time 
course data (not shown) revealed a main effect of time (F(11,748) = 49.664, p=<0.001) but no 
significant time x housing (F(11,803) = 1.461, p=0.141) or time x acute treatment interactions 
(F(33,748) = 1.405, p=0.0.067). The rearing data from two rats were excluded due to 
interruption of the upper beams by paw prints on the walls during recording but locomotor 
data were unaffected. 
3.5. Effect of acute cariprazine or aripiprazole on impairment in NOR caused by 
combined neonatal PCP treatment and social isolation 
Neonatal PCP combined with isolation rearing significantly impaired NOR (object x neonatal 
treatment/housing; F(1,70) = 15.915, P<0.001) which was reversed by cariprazine or 
aripiprazole (Fig. 4A, object x acute treatment; F(3,70) = 5.867, p<0.01). In the choice trial 
Veh/Soc/Veh rats were readily able to discriminate the novel from the familiar object as 
confirmed by the discrimination ratio (Fig. 4B). In contrast, neonatal PCP with social isolation 
significantly reduced the discrimination ratio (F(1,70) = 19.875, p<0.001) which was close to 
chance and this was robustly reversed (F(3,70) = 9.789, p<0.001) by either cariprazine (0.1 
and 0.3mg/kg) or aripiprazole. Irrespective of early-life treatment/housing or drug treatment 
none of the groups showed any preference for either the front or back object during the 
familiarisation trial (Table 2, F(1,70) = 0.812, p=0.371) and neither neonatal treatment/housing 
(object x neonatal treatment/ housing; F(1,70) = 0.177, p=0.676) nor drug treatment (object x 
acute drug treatment; F(3,70) = 1.582, p=0.202) affected this. Neither housing nor drug 
treatment had any significant effect on total object exploration during the familiarisation trial 
(Table 2, F(1,70) = 0.126, p=0.724 and F(3,70) = 2.351, p=0.080 respectively) but both had 
significant effects on total object exploration during the choice trial (PCP/housing; F(1,70) = 
10.524, Pp0.01) drug treatment; p<0.01, F(3,70) = 8.893, p<0.001). Total object exploration 
was significantly reduced between the first and second trials (main effect F(1,70) = 29.923, 
p<0.001) , but there were no significant trial x housing (F(1,70) = 3.962, p=0.050) or trial x drug 
treatment (F(3,70) = 0.144, p=0.144) interactions. 
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3.6. Effect of acute cariprazine or aripiprazole on social interaction in neonatal PCP 
social isolation rats 
As a potential index of change in negative symptoms of schizophrenia, seven weeks after 
weaning social interaction was recorded in an unfamiliar open field between pairs of weight 
and treatment matched rats from different litters that had never met before (Fig. 5). 
Repeated measures ANOVA of individual behaviors revealed significant behavior x housing 
(F(6,192) = 34.072, p<0.001) and behavior x drug treatment (F(18,192) = 2.001, p<0.05) 
interactions (Fig. 5). Of particular note anogenital and body sniffing were by far the most 
prevalent behaviors, accounting for over 80% of the total interaction time in most pairs 
(mean+SEM, 81.4+1.3), so it is particularly pertinent that the major changes were seen in 
these two behaviors. Anogenital sniffing and following were both significantly reduced in the 
PCP/Iso/Veh compared to that in Veh/Soc/Veh rats (anogenital sniffing; P<0.001, following; 
p<0.05) but neither cariprazine nor aripiprazole reversed this reduction. Conversely, body 
sniffing was significantly increased (p<0.001) in PCP/Iso/Veh compared to Veh/Soc/Veh rats 
and this was only attenuated (p<0.05) by the highest (0.3mg/kg) dose of cariprazine (and not 
aripiprazole). The small apparent increases in boxing and biting and crawling under and over 
in PCP/Iso rats did not reach significance from group-housed controls (Veh/Soc/Veh). The 
total social interaction time between pairs was unaffected by either housing (F(1,32) = 0.022, 
p=0.882) or drug treatment (F(3,32) = 1.514, p=0.230). In contrast both housing (F(1,32) = 
11.404, P<0.01) and drug treatment (F(3,32) = 21.336, p<0.001) significantly affected the 
distance travelled during the task (Fig. 6A), such that Veh/PCP/Veh pairs moved significantly 
more than Veh/Soc/Veh (p<0.01) rats. This increase in locomotor activity was reversed by 
aripiprazole (3mg/kg, p<0.001) and, in a dose-related manner, by cariprazine (0.1mg/kg 
P<0.05, 0.3mg/kg p<0.001) analogous to the effect observed in the novel arena. To further 
examine the impact of housing on social behavior the number of USVs emitted during 
interaction were also analysed as a potential index of change in communicative interaction, 
potentially highly relevant to human behavior. The total USVs emitted per pair was 
significantly increased by PCP/Iso (Fig. 6B, F(1,9.623) = 21.336, p<0.01) but unaffected by 
either cariprazine or aripiprazole (F(3,32) = 1.367, p=0.270). 
3.7. Effect of acute cariprazine or aripiprazole on fear conditioned freezing behavior 
in PCP and social isolation rats and group-housed controls 
During the CFR training process drug injection was not performed to avoid any confounding 
impact (such as alteration in perception of or aversion to the shock) on acquisition but data 
was analysed by drug sub-group to determine whether preceding treatment affected 
behavior during training and acquisition. Neither housing (F(1,70) = 0.638, p=0.427) nor drug 
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treatment (F(3,70) = 0.573, p=0.634) had any effect on the latency of rats to cross into the dark 
side of the box (data not shown). As expected freezing duration progressively increased on 
repeated exposure to the foot shock (F(1,70) = 108.886, p<0.001) and there was a significant 
interaction between foot shock x housing (F(1,70) = 6.902, p<0.05) although no foot shock x 
drug treatment interaction (F(3,70) = 0.657, p=0.581). 
There was a main effect of housing on freezing upon re-exposure to the context 24h later 
(F(1,70) = 6.687, P<0.05) such that the PCP/Iso/Veh froze less than Veh/Soc/Veh rats (Fig. 7, 
P<0.05) but neither drug was able to reverse this effect at this time (F(3,70) = 0.370, p=0.775). 
The change was similar at 48h post-conditioning (Fig. 7) such that PCP/Iso/Veh rats froze 
less than Veh/Soc/Veh controls (F(1,70) = 8.092, p<0.01) but this was also not altered by 
cariprazine or aripiprazole (F(3,70) = 2.145, p=0.102). The presentation of the conditioning cue 
significantly increased freezing duration (F(1,70) = 177.507, p<0.001), but this was unaltered 
by housing condition (F(1,70) = 3.612, p=0.061) or drug treatment (F(3,70) = 1.197, p=0.317). 
After the presentation of the cue the PCP/Iso/Veh rats also froze for significantly less than 
Veh/Soc/Veh (p<0.01) controls and although cariprazine and aripiprazole appeared to 
increase freezing above that in the PCP/Iso/Veh rats this did not reach significance (all 
p>0.05). 
3.8. Effect of repeated acute cariprazine or aripiprazole on body weight and plasma 
and brain drug levels in rats that have received combined neonatal PCP treatment and 
social isolation from weaning 
Up to the commencement of treatment with cariprazine or aripiprazole there was a 
significant effect of neonatal treatment on body weight (main effect; F(1,70) = 9.617, p<0.01, 
time x neonatal treatment/housing interaction; F(8,584) = 3.281, p<0.01) such that neonatal 
PCP isolated rats were significantly lighter (from PND 24 up to PND 59) than vehicle group-
housed controls. In contrast after commencing of regular drug injection (from PND 66) there 
were no significant differences in body weight between any of the groups. Blood plasma and 
brain levels of cariprazine and aripiprazole were determined 30min after the final injection (to 
coincide with peak behavioral effects, Table 3) in the PCP-isolation study. A previous study 
(Gyertyán et al., 2011) found that oral cariprazine (1mg/kg) produced a peak plasma 
concentration of 91ng/ml, which with linear pharmacokinetics would be expected to result in 
plasma concentrations of ~9 and ~30ng/ml with 0.1 and 0.3 mg/kg i.p., similar to those 
reported herein (6.6 and 33.4ng/ml, respectively). Furthermore the brain:plasma ratio for 0.1 
and 0.3 mg/kg i.p. cariprazine measured at a single time point herein (7.9:1 and 5.1:1 
respectively) are very similar to the value (7.6:1) reported by Gyertan et al. (2011) 
suggesting good CNS penetration with intraperitoneal administration. 
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4. Discussion  This study demonstrates that the D3-preferring D2/D3 dopamine receptor partial agonist, 
cariprazine, improves learning and memory in two rat models of cognitive impairment. In a 
delay dependent model of natural forgetting, both cariprazine and aripiprazole attenuated 
the impairment in NOR in a dose-related manner. In contrast neither drug had any adverse 
effects on the performance of NOR using a short (2 min) ITI. Cariprazine and aripiprazole 
are partial agonists at dopamine D3 receptors however cariprazine displays about 10-times 
higher affinity and potency in the in vitro binding and functional tests, respectively  than 
aripiprazole (Kiss et al., 2010; Tadori et al., 2011). Considerable previous work by ourselves 
and others suggest that blockade of the dopamine D3 receptor can improve cognition 
(Watson et al., 2012a), so this could be an important potential site of action most likely for 
cariprazine rather than aripiprazole, since the latter shows relatively low occupancy of D3 
receptors in vivo at pharmacologically-effective doses in rat studies (Gyertyán et al., 2011). 
Equally, it is known that blockade of the dopamine D2 receptor can attenuate visual learning 
and memory in this paradigm (Watson et al., 2012a). Thus, given that both drugs also have 
affinity for the dopamine D2 receptor it can be assumed that, at the doses used, there was 
either no significant antagonism at the D2 receptor or that any such effect was surmounted 
by actions at other receptors. It should also be noted that both drugs are relatively high 
affinity 5-HT1A receptor partial agonists in vitro (Kiss et al., 2010) but with low potency in 
lower lip retraction test in vivo (Gyertyán et al., 2011). As selective 5-HT1A receptor 
antagonists reverse impairments in NOR this mechanism could be an alternate or 
contributory factor to the pro-cognitive action seen in this study (Pitsikas et al., 2003). Both 
cariprazine and aripiprazole had no effect on total object exploration during either the 
familiarisation or choice trials. Thus, preferential increases in exploration of the novel object 
were the result of a redistribution of exploration and not the consequence of altered levels of 
activity as a result of any ‘sedative-like’ action of the drugs pointing to the specific nature of 
these effects on cognition.  
In addition, cariprazine and aripiprazole were equally active in reversing the NOR deficit in 
rats given neonatal PCP and housed in social isolation from weaning. Although PCP/isolate 
rats were hyperactive in an open field, analysis of this behavior shows they fail to habituate 
to the arena over time rather than having markedly enhanced locomotion at individual time 
points which could impair attention of objects in a short 3min NOR trial. Furthermore such 
hyperactivity would be expected to reduce total object exploration in both familiarisation and 
choice trials (which did not occur) and not account for a selective redistribution of the pattern 
of object exploration in the choice trial. Deficits in NOR performance are well documented 
following social isolation (Bianchi et al., 2006; Jones et al., 2011a; King et al., 2009; 
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McIntosh et al., 2013; Watson et al., 2012b) and combined neonatal PCP and social 
isolation but not neonatal PCP alone (Gaskin et al., 2014). Cariprazine has also been 
reported to have pro-cognitive effects in other rodent paradigms (Gyertyán et al., 2011; 
Zimnisky et al., 2013) and aripiprazole and cariprazine have been shown to reverse 
subchronic PCP-induced impairments in NOR in mice and rats (Nagai et al., 2009; Neill et 
al., 2015; Snigdha et al., 2008). It should be noted that changes in total object exploration 
were observed during the choice trial (main effects of both neonatal treatment/housing and 
drug treatment). However, analysis of the discrimination ratio, which takes differences in 
total object exploration between groups into account, suggests that the cognitive impairment 
in the PCP/Iso/Veh group was not confounded by any increase in total object exploration. Of 
particular note, cariprazine produced a dose-related reversal of the PCP-induced impairment 
of social recognition memory and delayed T-maze alternation in wild type mice but was 
unable to reverse these deficits in D3 receptor knockout mice (Zimnisky et al., 2013), 
consistent with the idea that partial agonist activity at this receptor may play an important 
contribution to this pro-cognitive effect in social recognition and spatial working memory. It 
would be valuable to assess the impact of cariprazine on PCP-isolation-induced impairments 
of other cognitive domains relevant to those impaired in schizophrenia, such as social 
cognition in future studies. 
Combined neonatal PCP and isolation caused the expected hyperactivity in a novel arena 
and during social interaction which was significantly reduced by cariprazine or aripiprazole. 
While neonatal PCP alone does not induce hyperlocomotion (Boctor and Ferguson, 2010) 
this is a consistent trait of social isolation attenuated by a range of antipsychotics, including 
haloperidol, risperidone and olanzapine (Fabricius et al., 2011; McIntosh et al., 2013). As 
hyperlocomotion probably results from increased mesolimbic dopamine, thought to 
contribute to positive symptoms of schizophrenia (Fone and Porkess, 2008), its attenuation 
herein supports the potential antipsychotic properties of cariprazine. 
Several studies have reported that isolation reared rats display reduced motivation for 
contact with conspecifics in social interaction (Moller et al., 2011; Van Den Berg et al., 1999). 
However there may be marked strain differences; Wistar rats showing decreased social 
behavior (such as approach, following, anogenital sniffing (Moller et al., 2011)) while Lister 
hooded rats show increased aggression without any major change in other behaviors (Fone 
and Porkess, 2008; Wongwitdecha and Marsden, 1996). Although total social interaction 
was unaffected by drug treatment or PCP/isolation, the most prevalent pro-social behaviours 
were significantly altered by the latter; decreased anogenital sniffing and following 
accompanied by increased body sniffing. Such that social interaction in Veh/Soc/Veh pairs 
was predominately nose to tail while that in PCP/Iso/Veh pairs was primarily nose to nose. 
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Only the highest dose of cariprazine (but not aripiprazole) significantly reduced the most 
prevalent pro-social behavior, body sniffing (by 20% from PCP/Iso/Veh rats), which may 
reflect a difference in effectiveness of cariprazine and aripiprazole at treating negative 
symptoms, which is worthy of further investigation. Consistent with the current findings the 
increase in avoidance and decrease in following behaviour produced by sub-chronic PCP 
administration to adult rats was also reversed by cariprazine (Neill et al., 2015). Using an 
identical PCP/isolate paradigm we found that clozapine (at doses which reversed the NOR 
deficit) was unable to restore the pro-social behavioural deficit (McIntosh et al., 2012), 
consistent with clozapine’s limited efficacy to treat the negative symptoms of schiziophrenia 
and supporting the potential translational value of this test.  
The USVs recorded in all groups were in the 50kHz range which occur in social, appetitive 
situations, during tickling and sexual behaviour thought to reflect positive affective state in 
rats (Brudzynski, 2013; Seffer et al., 2015). The increase in USVs in the socially isolated rats 
may reflect an increased motivation for social interaction although this was not accompanied 
by an increase in total social interaction compared to group-housed rats. At first sight the 
increase in USVs produced by PCP/Isolate rats would appear to be contradictory to that 
expected if this paradigm has any correlation to reduced sociability and social withdrawal 
seen in schizophrenia. However isolation-reared rats don’t show the normal approach 
response to playback of pro-social 50kHz calls (Seffer et al., 2015), consistent with the idea 
that they fail to mediate a normal response to socio-affective auditory information, which 
might contribute to the increased calls recorded in this study. Alternatively the increase in 
USVs may denote an increase in positive affect derived from the social interaction. USVs in 
the 50kHz range are associated with dopaminergic activity, being elicited by apomorphine, 
amphetamine and cocaine (Brudzynski et al., 2012; Mu et al., 2009; Wintink and Brudzynski, 
2001) but not by other psychostimulants, such as MDMA, caffeine or nicotine (Sadananda et 
al., 2012; Simola et al., 2012; Simola et al., 2010). Furthermore, direct stimulation of USVs 
by injection of quinpirole into the shell of the nucleus accumbens is mediated in a complex 
triphasic way by both dopamine D2 and D3 receptors (Brudzynski et al., 2012). Social 
isolation (without neonatal PCP) has been shown to increase basal dopamine release in the 
nucleus accumbens and enhance release in response to amphetamine (Hall et al., 1998), 
cocaine (Howes et al., 2000) and emotional stimuli (Fulford and Marsden, 1998). Thus the 
increase in USVs seen in PCP/isolated rats might represent an enhanced response resulting 
from the priming of the dopaminergic mesolimbic system. 
Although freezing following the first shock in CFR was significantly lower in PCP/isolates 
than controls both groups froze for an equivalent time after the second shock, indicating that 
both successfully responded to conditioning. Therefore, reductions in freezing following re-
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exposure to the context or cue probably result from a deficit in cognition rather than 
alteration in pain perception or emotional motivated associative learning. Attenuation of 
freezing in isolates in response to the context and cue are consistent with previous findings 
(Gaskin et al., 2014; Jones et al., 2011a; McIntosh et al., 2013) and may result from altered 
hippocampal and amygdala function (Goosens and Maren, 2001; Richmond et al., 1999). At 
no point did acute drug treatment with either cariprazine or aripiprazole significantly reverse 
the CFR deficit in the PCP/Iso/Veh group. Our previous studies have shown that neither 
risperidone nor the mGluR2/3 agonist, LY379268, could reverse the isolation-induced CFR 
deficit (Jones et al., 2011a; McIntosh et al., 2013), but that CFR is enhanced in control rats 
by drugs which modify central glutamatergic or cholinergic function such as 5-HT6 receptor 
antagonists (Woods et al., 2012). Indeed, isolation-induced deficits in CFR appear to involve 
impaired consolidation mediated by altered cholinergic, and not dopaminergic, regulation of 
the CREB cascade in the hippocampus (Okada et al., 2015). Impaired associative learning is 
a common symptom of schizophrenia showing limited response to existing antipsychotics 
(Herbener, 2009; Shohamy et al., 2010), so development of novel compounds which reverse 
this cognitive impairment in a rodent model may be a valuable addition to drug discovery. 
In summary, neonatal PCP combined with social isolation from weaning caused significant 
behavioral changes in locomotor activity, NOR, social interaction and CFR tasks. Acute 
cariprazine and aripiprazole reversed the hyperlocomotor activity and impairment in NOR. 
While, neither drug significantly affected the deficits seen in CFR, cariprazine, but not 
aripiprazole, modestly altered the changes seen in the most abundant prosocial behaviour 
during social interaction. Thus, cariprazine was as effective as aripiprazole in reversing the 
neurodevelopmental deficits thought to model positive symptoms and cognitive impairments 
seen in schizophrenia but, unlike aripiprazole, was also modestly effective in attenuating a 
model of the negative symptoms. In considering the translational relevance of this work it is 
important to note that the changes reported resulted from acute (albeit repeated) drug 
injection while chronic administration is essential before any clinical benefit from 
antipsychotics is observed. Furthermore, whilst many drugs operating through diverse 
pharmacological targets demonstrate pro-cognitive activity in preclinical tasks (e.g. NOR) 
and reverse indices of negative symptoms (e.g. social interaction), none have translated to 
proven efficacy in the clinic (Millan et al., 2014; Young and Geyer, 2015). Therefore further 
studies are essential to determine if multiple-hit developmental models such as this one 
provide more reliable predictive test beds for these vital unmet medical needs. 
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Figure 1 Both cariprazine and aripiprazole delay natural forgetting in a 4h ITI NOR 
paradigm. Comparison of the effect of cariprazine (A and B, 0.03-0.3mg/kg, 2ml/kg) and 
aripiprazole (C and D, 0.3-3mg/kg, 10ml/kg) injected i.p. 30min prior to the familiarisation 
trial in group-housed male Lister hooded rats (N=12, data shown as mean+SEM). A and C: 
Object exploration (s) during the second choice trial. B and D: Discrimination ratio (d2, novel 
object exploration – familiar object exploration/ total object exploration). In A: Repeated 
measures ANOVA showed an object x cariprazine treatment interaction (p<0.01), ** p<0.01, 
*** p<0.001 from the novel object in same treatment group, Bonferroni post-hoc test. In B: 
ANOVA showed a main effect of cariprazine treatment (P<0.001), *** p<0.01 from the 
vehicle group Dunnett’s post-hoc test. In C: Repeated measures ANOVA showed an object x 
aripiprazole treatment interaction (p<0.05), * p<0.05, *** p<0.001 from novel object in same 
treatment group, Bonferroni post-hoc test. In D: ANOVA showed a main effect of aripiprazole 
treatment (p<0.05), p=0.091 3mg/kg vs. vehicle group, Dunnett’s post-hoc test. 
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Figure 2 Both cariprazine and aripiprazole had no effect on NOR with a short (2min) ITI in 
which normal rats readily discriminate the novel from familiar object. Comparison of the 
effect of cariprazine (A and B, 0.03-0.3mg/kg, 2ml/kg) and aripiprazole (C and D, 
0.3-3mg/kg, 10ml/kg) injected i.p. 30min prior to the familiarisation trial in group-housed male 
Lister hooded rats (N=12, data shown as mean+ SEM). A and C: Object exploration (s) 
during the second choice trial. B and D: Discrimination ratio (d2, novel object exploration – 
familiar object exploration/ total object exploration). In A: Repeated measures ANOVA 
confirmed there was no object x cariprazine treatment interaction (p=0.087), *** p<0.001 
from novel object in same treatment group, Bonferroni post-hoc. In B: ANOVA confirmed no 
main effect of cariprazine treatment (p=0.100). In C: Repeated measures ANOVA confirmed 
there was no object x aripiprazole treatment interaction (p=0.882), *** p<0.001 from novel 
object in same treatment group, Bonferroni post-hoc. In D: ANOVA confirmed there was no 
significant effect of aripiprazole (p=0.886). Note as every rat received every dose and 
vehicle over four weeks the data also demonstrate the behaviour is reproducible and 
consistent in rats of comparable age. 
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Figure 3 Cariprazine and aripiprazole attenuated the hyperactivity in a novel arena produced 
by combined neonatal PCP and social isolation rearing from weaning of male Lister hooded 
rats. (A) Total locomotor activity and (B) number of rears (mean+SEM, N=14-16) measured 
by infra-red beam breaks in a novel arena over 1h. Behavior was recorded 6 weeks after 
weaning, following i.p. injection of either vehicle (2ml/kg), cariprazine (0.1 or 0.3mg/kg) or 
aripiprazole (3mg/kg in 10ml/kg) 30min prior to being placed in the arena. In A: two-way 
ANOVA showed a main effect of acute drug treatment (p<0.001) only, +++ P<0.001 from 
PCP/isolate/vehicle group, Bonferroni planned post-hoc comparisons. In B: two-way ANOVA 
showed a main effect of acute drug treatment (p<0.001) and of neonatal treatment/ housing 
(p<0.001), *** p<0.001 from vehicle/ social/ vehicle group; +++ p<0.001 from 
PCP/isolate/vehicle group, Bonferroni planned post-hoc comparisons. 
  
B A 
European Neuropsychopharmacology  
33  
 
 
Figure 4 Cariprazine and aripiprazole reversed the impairment in NOR in male Lister 
hooded rats produced by neonatal treatment with PCP and social isolation from weaning. 
Rats were injected i.p. with either vehicle (2ml/kg), cariprazine (0.1 or 0.3mg/kg) or 
aripiprazole (3mg/kg in 10ml/kg) 30min prior to familiarisation trial and data shown is 
exploration recorded from the choice trial 2h later, mean+SEM, N=14-16. A: Novel and 
familiar object exploration time (s). B: Discrimination ratio (d2, novel object exploration – 
familiar object exploration/ total object exploration). In A: RM-ANOVA showed a significant 
object x neonatal treatment/ housing interaction (p<0.001) and a significant object x acute 
drug treatment interaction (p<0.01), *** P<0.001 from the novel object in same treatment 
group, Bonferroni post-hoc. In B: two-way ANOVA showed significant main effects of 
neonatal drug treatment/ housing (p<0.001) and acute drug treatment (p<0.001), *** p<0.001 
from vehicle/social/vehicle group; ++ p<0.01, +++ p<0.001, from PCP/isolate/vehicle group, 
Bonferroni planned post-hoc comparisons. 
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Figure 5 Comparison of the effect of cariprazine (Car at the dose indicated in the legend) 
and aripiprazole (Ari) on social interaction in male Lister hooded rats treated with neonatal 
PCP and socially isolated from weaning. Social interaction (s, mean+SEM, of the mean time 
for each pair) between two rats of similar weight from different litters but the same 
developmental condition and drug treatment over a 10min trial, N=7-8 pairs. Rats were 
injected i.p. with either vehicle (2ml/kg), cariprazine (0.1 or 0.3mg/kg) or aripiprazole (3mg/kg 
in 10ml/kg) 30min prior to the trial. Repeated-measures ANOVA revealed a significant 
behavior x neonatal treatment/housing interaction (p<0.001) and a significant behavior x 
acute drug treatment interaction (P<0.05), * p<0.05, *** p<0.001 from vehicle/social/vehicle 
group for that behavioral component; + p<0.05 from PCP/isolate/vehicle group in that 
behavior, Bonferroni planned post-hoc comparisons. Note the different time scale used to 
report anogenital and body sniffing (which account for over 80% of the total interaction time 
in most pairs) and the other much less frequent behaviors. 
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Figure 6 Effect of cariprazine and aripiprazole on social interaction in male Lister hooded 
rats treated with neonatal PCP and socially isolated from weaning. Social interaction 
between two rats of similar weight from different litters but the same developmental condition 
and drug treatment over a 10min trial, n=7-8 pairs. The average time spent in each 
behavioral component for each pair is presented as mean+SEM and rats received i.p. 
injection with either vehicle (2ml/kg), cariprazine (0.1 or 0.3mg/kg) or aripiprazole (3mg/kg in 
10ml/kg) 30min prior to trial. Figures show the total; A: locomotor distance (cm) covered and 
B: number of ultrasonic vocalisations (USV) per pair during the 10min trial, following a log10 
transformation to normalise USV data. In A: Two-way ANOVA showed a main effect of 
neonatal treatment/ housing (p<0.01) and acute drug treatment (p<0.001), ** p<0.01 from 
vehicle/ social/vehicle group; + p<0.05, +++ P<0.001 from PCP/ isolate/vehicle group, 
Bonferroni planned post-hoc comparisons. In B: Two-way ANOVA showed a main effect of 
neonatal treatment/ housing (p<0.01) but no effect of acute drug treatment (p=0.270). 
* p<0.05 from vehicle/social/vehicle group, Bonferroni planned post-hoc test. 
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Figure 7 Effect of cariprazine (Car at the dose indicated) or aripiprazole (Ari) on the 
retention and extinction of memory in a fear motivated conditioned freezing response in 
controls or male Lister hooded rats treated with neonatal PCP and socially isolated from 
weaning. Rats received i.p. injection of either vehicle (2ml/kg), cariprazine (0.1 or 0.3mg/kg) 
or aripiprazole (3mg/kg in 10ml/kg) immediately after fear conditioning (three 1s 0.4mA foot 
shocks accompanied with light and tone cue delivered with a 55s delay between each 
cue/foot shock) and 30min prior to assessment of memory at 24h and 48h post-conditioning. 
Data shown is freezing time. Total time (s, mean+SEM, n=14-16) spent freezing was 
recorded following reintroduction (for 5min) into the conditioning chamber at 24h and 48h 
later and (at 48h only) with presentation of the light and tone cue. At 24h, two-way ANOVA 
showed a significant effect of neonatal treatment/ housing (p<0.05) but no effect of acute 
drug treatment (p=0.775). At 48h repeated-measures ANOVA showed a significant effect of 
cue (p<0.001) and a main effect of neonatal treatment/housing (P<0.01) but no main effect 
of acute drug treatment or any interactions (all p>0.05), * p<0.05, ***p<0.01 from vehicle/ 
social/ vehicle group at that time point, Bonferroni planned post-hoc comparisons. 
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Table 1 Object exploration during the familiarisation and choice trials.  
                  Familiarisation Trial Choice Trial 
Intertrial Interval Drug Dose Front Object (s) Back Object (s) Total Exploration (s) Total Exploration (s) 
4h Cariprazine  Vehicle 0.03 mg/kg 0.1 mg/kg 0.3 mg/kg 
11.2 (1.2) 14.6 (1.3) 13.4 (1.7) 9.2 (1.4) 
10.9 (1.3) 12.4 (1.1) 13.5 (1.2) 10.7 (1.4) 
22.1 (2.4) 27.0 (2.2) 26.9 (2.3) 20.0 (2.1) 
15.6 (2.0) 13.0 (1.7) 14.9 (1.4) 12.0 (1.7) 
4h Aripiprazole Vehicle 0.3 mg/kg 1 mg/kg 3 mg/kg 
10.7 (1.2) 10.9 (1.2) 13.9 (1.5) 13.1 (1.5) 
10.3 (1.0) 13.3 (2.0) 13.3 (1.3) 11.3 (0.8) 
21.0 (2.0) 24.3 (3.0) 27.2 (2.5) 24.4 (2.0) 
16.7 (2.3) 18.8 (1.2) 17.0 (2.0) 16.6 (2.5) 
2min Cariprazine Vehicle 0.03 mg/kg 0.1 mg/kg 0.3 mg/kg 
10.7 (0.8) 10.3 (1.0) 8.6 (1.2) 6.4 (1.4) 
8.9 (1.2) 9.5 (1.1) 9.7 (0.9) 7.1 (1.1) 
19.7 (1.8) 19.9 (2.0) 18.3 (2.0) 13.5 (2.3) 
12.3 (1.7) 16.3 (1.6) 11.9 (1.9) 11.4 (1.4) 
2min Aripiprazole Vehicle 0.3 mg/kg 1 mg/kg 3 mg/kg 
9.5 (0.9) 10.7 (0.9) 9.3 (0.9) 7.0 (1.1) 
9.0 (0.9) 10.8 (1.3) 10.3 (1.0) 8.1 (1.2) 
18.5 (1.7) 21.5 (2.1) 19.6 (1.6) 15.2 (1.7) 
14.7 (1.6) 15.1 (1.7) 13.8 (1.8) 12.4 (1.8) 
 Neither cariprazine (0.03-0.3mg/kg) nor aripiprazole (0.3-3mg.kg i.p.) given 30min prior to 
the familiarisation trial in group-housed male Lister hooded rats had any effect on the 
distribution of object exploration time (mean (SEM), N=12 each drug group) during any of 
the familiarisation trials (all p>0.05). There was a significant reduction in object exploration 
during the choice compared to the familiarisation trial in all experiments (all p<0.001) but 
drug treatment did not significantly alter the total object exploration time during any 
familiarisation or choice trial (all p>0.05). Thus the both drugs altered the pattern of object 
exploration during the choice trial without affecting the total choice trail object exploration 
time, suggesting there was no confounding non-specific effect of the drugs on attention of 
the objects and no major ‘sedative-like’ effect of either drug at the doses used. 
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Table 2 Object exploration during the familiarisation and choice trials. 
Intertrial Interval 
Neonatal Treatment/ Housing Drug Treatment 
               Familiarisation Trial Choice Trial 
Front Object (s) Back Object (s) Total Exploration (s) Total Exploration (s) 
2h ITI         Vehicle/ Group PCP/ Isolate PCP/ Isolate PCP/ Isolate PCP/ Isolate 
Vehicle Vehicle Cariprazine (0.1mg/kg) Cariprazine (0.3mg/kg) Aripiprazole (3mg/kg) 
17.7 (1.4) 17.8 (1.1) 17.5 (1.5) 15.0 (1.4) 14.4 (1.4) 
17.2 (1.3) 18.2 (1.2) 14.7 (1.2) 13.0 (1.9) 16.4 (1.3) 
34.9 (2.1) 36.0 (1.7) 32.1 (1.8) 28.0 (3.0) 30.8 (2.1) 
25.0 (2.3) 33.9 (2.3) 20.9 (1.4) 24.2 (1.9) 25.0 (1.7)  
  Neither cariprazine (0.1 or 0.3mg/kg) nor aripiprazole (3mg.kg) injected i.p. 30min prior to 
the novel object discrimination task had any effect on the pattern of object exploration (s) 
during the familiarisation trial either in controls or rats treated with neonatal PCP and social 
isolation from weaning (all p>0.05). There was a significant reduction in exploration in the 
choice compared to the familiarisation (p<0.001) trial which was accompanied by a main 
effect of neonatal drug treatment/ housing (p<0.001) and acute drug treatment during the 
choice trial (p<0.01). Data shown as mean (SEM), N=14-16. 
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Table 3 Drug concentrations in blood plasma and brain tissue.  
Drug Treatment Blood Plasma (ng/ml) Brain (ng/g) 
Cariprazine (0.1mg/kg) Cariprazine (0.3mg/kg) Aripiprazole (3mg/kg) 
6.6 (0.8) 33.4 (3.7) 93.5 (9.2) 
52.0 (3.0) 171.8 (23.0) 127.3 (19.6) 
 
Blood plasma (ng/ml) and brain tissue (combined right frontal cortex and right hippocampus, 
ng/g) concentrations were determined 30min after injection of cariprazine (0.1 or 0.3mg/kg) 
or aripiprazole (3mg/kg) i.p. in male Lister hooded rats treated with neonatal PCP and then 
housed in social isolation from weaning. Drug concentrations were determined using liquid 
chromatography–mass spectrometry. Data shown as mean (SEM), N=14-15.  
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Figure 5 Comparison of the effect of cariprazine (Car at the dose indicated in the legend) and 
aripiprazole (Ari) on social interaction in male Lister hooded rats treated with neonatal PCP and 
socially isolated from weaning. Social interaction (s, mean+SEM, of the mean time for each pair) 
between two rats of similar weight from different litters but the same developmental condition and 
drug treatment over a 10min trial, N=7-8 pairs. Rats were injected i.p. with either vehicle (2ml/kg), 
cariprazine (0.1 or 0.3mg/kg) or aripiprazole (3mg/kg in 10ml/kg) 30min prior to the trial. Repeated-
measures ANOVA revealed a significant behavior x neonatal treatment/housing interaction (p<0.001) 
and a significant behavior x acute drug treatment interaction (P<0.05), * p<0.05, *** p<0.001 from 
vehicle/social/vehicle group for that behavioral component; + p<0.05 from PCP/isolate/vehicle group 
in that behavior, Bonferroni planned post-hoc comparisons. Note the different time scale used to 
report anogenital and body sniffing (which account for over 80% of the total interaction time in most 
pairs) and the other much less frequent behaviors. 
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